Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-8490 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| CC-8490 | DRUG | - |
Inclusion Criteria: * Patients with glioblastoma multiforme (GBM), gliosarcoma, anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), malignant glioma/astrocytoma NOS (not otherwise specified). Also included will be radiographically diagnosed infil...
CC-8490 is an investigational small molecule being studied for the treatment of glioblastoma, a type of high-grade glioma. It was evaluated in patients with recurrent or refractory high-grade gliomas, including glioblastoma and malignant gliomas.
CC-8490 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company sponsored a Phase 1 clinical trial of the drug in the United States.
CC-8490 is in Phase 1 clinical development. A Phase 1 trial of the drug has been completed, and it remains an investigational agent that has not been approved by regulatory authorities.
CC-8490 has been studied in one completed clinical trial, NCT00074646, titled 'Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas.' The trial enrolled 36 participants in the United States.
CC-8490 is a small molecule, but its specific molecular target has not been disclosed. The Phase 1 trial did not select patients based on biomarkers, and the study was uncontrolled, meaning there was no comparison group.